Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oratecan in Advanced Malignancies
NCT02250157Phase 1Completed
- Sponsor
- Athenex
- Start
- Sep 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of encequidar in solid tumor (2 arms), sponsored by Athenex. Primary endpoint: Dose Limiting Toxicities at 2 years. Started Sep 2014; status: completed.
02
Drugs
encequidar
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02250157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250157.